EGFR and non-small cell lung carcinoma: Median overall survival of NSCLC patients with BMs ranged from 3 to 15 months in an unselected population without EGFR-tyrosine kinase inhibitors (EGFR-TKIs) targeted therapy (5, 6), and 18 to 58 months in EGFR-mutant patients with EGFR-TKIs treatment (7, 8).